innovotech annual general meeting presentation 2010
DESCRIPTION
TRANSCRIPT
www.innovotech.ca © Innovotech, 2009
Annual General Meeting
20 April 2010Edmonton, Alberta
Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
A G E N D A Welcome Formal Administrative Business Adjournment of AGM Business Update Q&A
Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
Formal Administrative Business
Innovotech Inc.
www.innovotech.ca © Innovotech, 2009
Election of Directors: Dr Lorne Babiuk Mr Kerry Brown Mr Bruce D. Hirsche Q.C. Dr Wolfgang H. Muhs Mr John Pinsent Dr Gerard Tertzakian Dr James Timourian
Innovotech Inc.
Innovotech Business Update
www.innovotech.ca © Innovotech, 2009
2009 – Moving to Market
Objectives & Performance in 2009
www.innovotech.ca © Innovotech, 2009
2009 Financial Results
2009 2008Revenue $1,453,924 $1,164,035
Gross Margin $813,629 $695,409
Overhead Costs $984,178 $909,588
R&D Expenditures $809,326 $708,007
EBIT ($1,136,783) ($983,261)
Accumulated Deficit ($3,618,938) ($2,491,735)
Shares Outstanding (wa) 23,985,784 21,907,352Cash Reserves (Dec 31) $1,375,559 $2,120,859
www.innovotech.ca © Innovotech, 2009
bioFILM PA - Objectives
bioFILM PA goals for 2009: Revenue Expand through commercial partner
Path: Canada: Maintain current plan USA: “Research Use Only” through Partner Convert to dry panel
www.innovotech.ca © Innovotech, 2009
bioFILM PA -Stakeholders
LaboratoryUser
DoctorsDecision-maker
Alberta HealthPayer
IOT
PatientsRecipient
www.innovotech.ca © Innovotech, 2009
bioFILM - Market potential
Market - bioFILM PA: Canada US World Cystic Fibrosis $2.4M $24M $50M Ventilator Associated Pneumonia $35M $70M Other (burns, wounds) tbd
Market – bioFILM SA: Canada US World Catheters Dialysis Other (CF, VAP)
Total >$150M
www.innovotech.ca © Innovotech, 2009
bioFILM PA – 2010 Objectives
Revenue in Canada Published paper Health economic evaluation
Enter other markets US through private diagnostic laboratory Israel
SA development Low cost and quick development Augments PA disease use (CF and VAP)
www.innovotech.ca © Innovotech, 2009
Agress – Objectives
Agress goals for 2009: Regulatory approval for pulses Commercial agreement
Path: Maintain current Co interest Potential reg filing for Fire Blight Develop AUS R&D Launch in N America for pulses post-09
www.innovotech.ca © Innovotech, 2009
Agress – PMRA (Canada)
Current situation: Innovotech denied waiver
claims Asked to re-submit with
expedited review for approved components
Fees partially refunded 4 crops, 13 diseases, 1 use
pattern
New submission: Determine EPA stance Use Syngenta regulatory
team Evaluate current consultants 8 crops, 25 diseases, 2 use
patterns
www.innovotech.ca © Innovotech, 2009
Agress – Syngenta partnership
Agress to be used as “anti-bacterial” component of many products
Syngenta press release on partnership Post-trade show orders of 1.5kg of Agress Syngenta (US) interest in Pithium data in corn
www.innovotech.ca © Innovotech, 2009
Agress – 2010 Objectives
Expand product claims Crop, Disease and Use pattern Incorporate Syngenta trials
Remove regulatory hurdles Meet with agencies Draw on external scientific expertise
Maintain flexibility with other companies
www.innovotech.ca © Innovotech, 2009
Silver Periodate opportunity
Unique properties Patentable discovery Interest of medical device and agriculture companies Assembly of internal team
www.innovotech.ca © Innovotech, 2009
2010 – Objectives
Our goals for 2010: bioFILM PA™
Agress
R&D
Contract Research
Revenue Enter US market Expand claims Remove regulatory hurdles Product candidate from Silver periodate Develop bioFILM SA Photo-dynamic approval as sanitizer Revenue growth
www.innovotech.ca © Innovotech, 2009
Contact Information
Ken Boutilier, President Innovotech [email protected]: 780-448-0585 ext 221Fax: 780-424-0941
www.innovotech.ca © Innovotech, 2009
www.innovotech.ca © Innovotech, 2009
2008 Summary - Agress™
Seed Treatment, Pulse cropsNorth America$3-5M
Seed Treatment, All cropsNorth America$120M
Seed & FoliarAll crops
World$20B+
Factors: Treatment is based on disease pressure Crop guarantees by sellers increasestreatments A suitable antibacterial is lacking Formulations are as important as “actives” Agress will be in a combination with other agents
www.innovotech.ca © Innovotech, 2009
Agress – Market Potential
Vegetables/Horticulture
Fruit Trees/Bushes
Pulses
Soybeans
Cereals
Corn
Canola
0%
20%
40%
60%
80%
100%
-$500 $500 $1,500 $2,500 $3,500 $4,500
Trea
tmen
t Int
ensit
y (%
)
Value/Acre ($/ac)
Markets
Agress is price competitive in all markets!